Future of cord blood for non-oncology uses

G. Kögler, P. Critser, T. Trapp, M. Yoder

Research output: Contribution to journalReview article

39 Scopus citations

Abstract

For the last 5 years cord blood (CB) has been under intense experimental investigation in in vitro differentiation models and in preclinical animal models ranging from bone to muscle regeneration, cardiovascular diseases including myocardial and peripheral arterial disease, stroke and Parkinson's disease. On the basis of its biological advantages, CB can be an ideal source for tissue regeneration. However, in the hype of the so-called plasticity, many cell types have been characterized either on cell surface Ag expression alone or by RNA expression only, and without detailed characterization of genetic pathways; frequently, cells are defined without analysis of cellular function in vitro and in vivo, and the definition of the lineage of origin and cells have not been defined in preclinical studies. Here, we explore not only the most consistent data with regard to differentiation of CB cells in vitro and in vivo, but also show technical limitations, such as why in contrast to cell populations isolated from fresh CB, cryopreserved CB is not the ideal source for tissue regeneration. By taking advantage of numerous CB units discarded due to lack of sufficient hematopoietic cells for clinical transplantation, new concepts to produce off-the-shelf products are presented as well.

Original languageEnglish (US)
Pages (from-to)683-697
Number of pages15
JournalBone marrow transplantation
Volume44
Issue number10
DOIs
StatePublished - Nov 1 2009

    Fingerprint

Keywords

  • Differentiation of CB cells
  • Regenerative therapeutics
  • Stem cells
  • Tissue regeneration

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this